Antiviral Therapy Resources for Providers: COVID-19 - Minnesota Dept. of Health

Antiviral Therapy Resources for Providers: COVID-19

Antiviral Resources: medication bottle and IV bag icons

Designed for health care providers, facilities, and systems as a compilation of resources for determining eligibility and prescribing outpatient treatment for acute COVID-19.

Clinical considerations

Determining eligibility and choosing a treatment

Prescribing tools

Important considerations when prescribing treatment

Accessing antiviral treatment

Where to access and prescribe

  • Covid-19 Test to Treat Locator
    Enter an address or zip code to search for:
    • Locations with testing, medical visits and medication (Test-to-Treat)
    • Locations to fill a prescription
    • Pharmacy locations with available oral antiviral inventory (including type) can be found using this locator.

  • HHS COVID-19 Therapeutics Locator
    National map displaying locations that have received supplies of COVID-19 therapeutics, including Paxlovid, molnupiravir, bebtelovimab, and Evusheld.

    Note: As of 3 p.m. on June 30, 2022, the MNRAP platform is no longer available for referrals. Providers who wish to refer a patient for bebtelovimab may use the HHS COVID-19 Therapeutics Locator to find health care facilities that have received shipments of COVID-19 therapeutics. Data in this locator is based on stock on hand reported by locations within the past two weeks and is not a guarantee of availability.
  • Where to Access Oral Antiviral Therapy in Minnesota
    Patients or providers can contact health systems and clinics listed to ask about availability of oral antiviral medications or access the federal Test-to-Treat program.

  • Remdesivir is available commercially and is not being distributed by the federal government. Due to logistical constraints, outpatient remdesivir is not widely available. Providers should check with their nearest hospital or infusion center to see whether outpatient remdesivir treatment can be arranged. Infectious disease consultation may be required.

  • Bebtelovimab is expected to become commercially available on around Aug. 15, 2022. Facilities who have previously received monoclonal antibodies through the distributor (Amerisource Bergen) will receive an email from the distributor with instructions regarding commercial purchase. Facilities that have not previously received monoclonal antibodies and are interested in purchasing bebtelovimab should contact Amerisource Bergen at to register for an account.

  • Providers who are not currently receiving distributions of Evusheld, but are interested in small volume ordering (1-3 patient courses), may now place those orders directly with the federal government at EVUSHELD Small Volume Order Form. AstraZeneca has established a helpline for providers with questions about prescribing and ordering at 1-833-EVUSHLD (833-388-7453).

General resources

Updated Wednesday, 10-Aug-2022 15:42:19 CDT